Member Info for rhwillcoll

Interesting that we have already had 13 million sells today, but that is excluding any "blue" ones earlier on. A definite overhang, rather than traders selling. Not least, there is a regularity to the selling. One can see this in the general share price since 9 June.

BUT, good news is that we really are nearing the end of all this. Additionally, the MMs will certainly not be informing us once they have no stock left.

Looking forward to having normal buying/selling and to further good news from the company. It will most certainly happen quite soon, in my opinion, and I am very optimistic re the company and its prospects. A proper nuisance, though.

Hi Comek2, I think we are on the same page re the books (!). Basically yes I entirely agree with you that eg Author42 would sell really well in China.

What I was saying was something different. It was which country is number 1, 2 and 3 in the world for total AI innovation - all companies and all ai: the answer to this is 1 USA, 2 China and 3 UK. And that capAI is strongly in USA and UK. It was really that tomorrow will be Mr Trump's big AI rollout for the USA, throwing $90 bn at it, as he wants it to remain at number 1 in the world. Actually I am surprised that the UK is number 3.

All the very best, and I trust that this provides some clarification.

Just filtered two trolls - Imm and Warr. What a waste of space.

Suggest others do the same.

Life is simply too short to engage, and anyway they can jolly well do their own research, just like the rest of us.

I think that we are "virtually" at the end of those pesky warrant sales.

We know that these were issued on 9th June - that is, we are now at day 32 of the 400 million warrant sales. I have done my best to monitor these sales

over recent days. It seems like 10-13 million sales on each and every day. At 10 million sales a day, that is 80% through.

At start of selling, they were selling for around 44p or so. Today, it has been 38p. Normally with the "last lot", they reduce the price to simply get rid of the "last of the bunch". By my very rough "science," I would conjecture (and it is only that) that we are almost there now, and then we shall be free of this overhang.

In fact, just in time for "The Official USA AI Day" tomorrow, which really will be for capAI's benefit.

So, well done, you patient co-investors. VERY close now to being free.

Imho, Dyor

6 Million buys since 12 noon.

A lot of large buys are coming in now on level 2.

It's looking good, in my opinion.

Comek2, great post at 9.52, I agree with you. An overhang. I think that soon, this will all be over and done with, and then we'll all be really happy and comfortable to be in a great company building a massive empire.

Apparently it's tomorrow that we have the Trump AI day - is it something like 90 billion USD their Govt is giving, so that USA will be top AI in the world. No 2 China, and No 3 the UK. So, we are in numbers 1 and 3, with pots of money being thrown at us! Yes please Sir, I'll take some more!

What new AI innovations could emerge from capAI and R42 collaboration

The strategic partnership between capAI and R42 Group positions both companies to catalyse significant breakthroughs in artificial intelligence, largely within the fields of media, content creation, and medical research. Leveraging combined networks, expertise, and capital efficiency, several innovative AI projects are already in the review and development pipeline.

Key Areas of Emerging AI Innovation

1. AI in Content Adaptation and Creation

Book-to-Movie Adaptation Platform

AI systems that automatically convert books and literary works into cinema-quality screenplay adaptations. This technology can streamline and democratise the process of turning written stories into film-ready scripts.

Book-to-Game Technology

AI engines capable of transforming narrative content from books into interactive game storylines and formats, unlocking new monetization channels for intellectual property.

AI Media Creator for Multi-Format Content

Tools designed to generate and adapt creative works (books, screenplays, etc.) across multiple media formats autonomously, opening up rapid content diversification.

2. AI-Driven Medical Research and Biotechnology

AI for Aging Vaccine Research

Advanced AI to explore and accelerate research into vaccines or therapies targeting cellular aging, potentially impacting longevity science and preventative medicine.

Automated Scientific Discovery Systems

AI platforms built to automate hypothesis generation, data analysis, and even experimental design to accelerate discoveries in life sciences, medicine, and beyond.

Diagnostic AI in Healthcare

Expansion into AI systems for medical diagnosis and drug discovery, such as AI-assisted cancer diagnostics and biotechnology platforms that identify novel drug-disease relationships with high success probability.

3. Flexible Incubation and Transatlantic Innovation

Joint Incubation of Unnamed AI Startups

The alliance provides a framework for rapidly co-incubating external projects, offering the agility to pursue emerging, high-growth opportunities across both established and novel AI verticals, as warranted by market conditions and technological advances.

I'm just concentrating on the news, which is totally good. However, I still think we have a few warrants to be sold. It won't last long in the grand scheme of things. Once they're gone, we'll have a superbly booming time.

23 trades, and 23 buys.

The BLUE touch paper has been lit.

Start of commercial and operational activities- and a further four media companies to shortly be part of the capMedia empire building.

Well done company, well done investors!

As as addition to my post below, just to add that 13 million shares have just been added after hours. To me, given timings and prices, these all appear to be buys.

Sorry to ask a silly question. I've just looked at L2 and I see that there have been seven chunky sells this afternoon, well over a million and each of £5,000 each. The good news is that there were many buys in the last hour or so, taking up the slack.

My simple question: are these warrants all sold now, or are there still some going through?

This company will I'm sure take off again quite soon, but just to ask people whether we have warrants still to go through, that is all.

United States AI Action Plan (July 2025)

Overview

The current U.S. AI Action Plan is shaped by a major policy shift in early 2025 under President Trump. The aim is to remove barriers to American AI leadership and drive innovation, economic competitiveness, and national security through decisive federal action. This strategy marks a departure from the previous administration’s approach, emphasising fewer regulatory burdens and more support for private and public sector innovation.

Key Elements of Today’s Action Plan

1. Executive Order and Leadership

Executive Order 14179 ("Removing Barriers to American Leadership in Artificial Intelligence") was signed on January 23, 2025, by President Trump.

Immediately revoked Biden-era AI restrictions, particularly the 2023 Executive Order 14110, which was seen as imposing overly restrictive requirements on private sector AI development.

The plan development is led by the Assistant to the President for Science and Technology, National Security Advisor, and the White House AI and Crypto Czar.

2. Focus Areas and Policy Actions

Promote innovation by removing obstacles to private-sector AI development.

Public-private R&D partnerships to address fundamental AI research challenges and next-generation hardware.

Revised guidance for federal agencies on AI adoption and procurement, cutting bureaucracy and focusing on efficiency and effectiveness.

Workforce development including staff upskilling, and the appointment of Chief AI Officers across government agencies.

Prioritization of national interests: Security, defense, and protecting U.S. critical infrastructure are highlighted.

AI explainability, assurance, and security are now central to federal policies, alongside data privacy protections.

National AI R&D Strategic Plan for 2025 aligns federal priorities around research that the private sector is unlikely to address, such as fundamental AI algorithms, security, education, and human-AI interaction.

3. Streamlined Government Use

New regulations released in April 2025 accelerate AI adoption in federal agencies, streamline acquisition, and require the creation of AI compliance plans.

Exempts certain AI used in national security systems from standard federal requirements.

Chief AI Officer Council established to improve coordination and knowledge-sharing across various departments.

4. Solicitation of Public and Expert Input

Ongoing requests for comment from the public and stakeholders on priority actions, reflecting an emphasis on inclusive, adaptive policy setting.

Representative Initiatives

National Security: Development of early warning systems for AI-driven threats and promotion of AI trustworthiness.

Infrastructure: Preparing U.S. energy infrastructure for AI-driven growth and supporting collaborative datasets in life sciences.

Talent: Initiatives to attract top global talent to strengthen national security and economic competitiveness through AI

Whilst Prof Nag has no direct association with the supercomputer at Bristol, I think as has been indicated here, that R42 is actively working on many cancers eg with FSA approved medicines which could quickly be brought out, they're working on eg dementia and alzheimer's etc etc. Both diagnostically and treatment-wise.

The point I wish to make is that Prof Nag already has a lot of IP in place, and these are massive illnesses and markets that need a number of major breakthroughs. Also, it is my understanding that these kinds of conditions will come under the R42 and capAI umbrellas. It is all extremely exciting, to say the least.

A lot of buys have come in during the last hour or so. I've just checked in. Now checking out, as I have more than enough shares and am happy to just sit tight in the knowledge that an awful lot is happening within the company here underneath the bonnet, without feeling the itch to daily go after other stocks.

Each to their own, but I have other things to do, not least writing my second book! I think too that most investors in capAI are just sitting tight and doing other things. Well done! Even 100,000 invested here will imho yield a lovely profit, with a little patience.

Which medical solutions are r42 prof nag involved with:

Medical Solutions Involving R42 and Prof. Ronjon Nag

Professor Ronjon Nag, as founder and president of the R42 Group, is deeply involved with medical and longevity technologies, particularly at the intersection of artificial intelligence (AI), biotechnology, and healthcare. Below are the key medical solutions and initiatives he is associated with:

1. Agemica: Vaccine for Aging

Focus: Developing a vaccine targeting the biological processes of aging.

Objective: To slow or alter the mechanisms of aging, aiming to extend healthy human lifespan.

Role: Prof. Nag is CEO and a driving force behind Agemica, which represents a major step toward “aging vaccines”.

2. Superbio.ai: AI Life Sciences Platform

Focus: No-code platform for building AI applications in life sciences.

Objective: Empower researchers to create, deploy, and share life science AI apps without programming knowledge.

Innovation: Superbio.ai serves as an “AI app store” that lowers barriers for medical and biological researchers, streamlining AI-driven discoveries.

3. NeuroAge Therapeutics

Focus: AI-driven platform for brain aging assessment and drug discovery.

Key Solutions:

Personalized Brain Health Assessment: Uses AI to analyze MRI, biomarkers, cognitive tests, and genetics to estimate brain aging and dementia risk decades before symptoms.

Drug Development: Identifies gene targets and designs drugs tailored to rejuvenate the brain.

Recognition: Funded by the Alzheimer’s Drug Discovery Foundation; recognized as an innovator in longevity and neurodegeneration biotechnology.

4. Full-Body MRI and Brain Health Solutions

Focus: Offering advanced, AI-enhanced full-body MRI scans.

Application: Includes dementia and neurodegeneration risk analysis.

Integration: Solutions like those provided via capAI are closely linked to R42 and offer early detection and preventative strategies for age-related diseases.

5. AI in Healthcare and Longevity

General Investments: R42’s portfolio includes numerous early-stage companies applying machine learning and computational biology to extend healthspan, discover new therapeutics, and develop diagnostics.

Community Initiatives: Prof. Nag educates through Stanford courses and the R42 Institute, teaching about AI, genetics, longevity, and ethics in medicine.

(Source: Updated Perplexity App)

Personally I think capAI will receive either most or all of the above companies. We don't know yet, or the percentage, which could be 50/50 with R42?

What new AI innovations could emerge from capAI and R42 collaboration

Potential New AI Innovations from capAI and R42 Collaboration

The strategic partnership between capAI and R42 Group positions both companies to catalyze significant breakthroughs in artificial intelligence, largely within the fields of media, content creation, and medical research. Leveraging combined networks, expertise, and capital efficiency, several innovative AI projects are already in the review and development pipeline.

Key Areas of Emerging AI Innovation

1. AI in Content Adaptation and Creation

Book-to-Movie Adaptation Platform

AI systems that automatically convert books and literary works into cinema-quality screenplay adaptations. This technology can streamline and democratize the process of turning written stories into film-ready scripts.

Book-to-Game Technology

AI engines capable of transforming narrative content from books into interactive game storylines and formats, unlocking new monetization channels for intellectual property.

AI Media Creator for Multi-Format Content

Tools designed to generate and adapt creative works (books, screenplays, etc.) across multiple media formats autonomously, opening up rapid content diversification.

2. AI-Driven Medical Research and Biotechnology

AI for Aging Vaccine Research

Advanced AI to explore and accelerate research into vaccines or therapies targeting cellular aging, potentially impacting longevity science and preventative medicine.

Automated Scientific Discovery Systems

AI platforms built to automate hypothesis generation, data analysis, and even experimental design to accelerate discoveries in life sciences, medicine, and beyond.

Diagnostic AI in Healthcare

Expansion into AI systems for medical diagnosis and drug discovery, such as AI-assisted cancer diagnostics and biotechnology platforms that identify novel drug-disease relationships with high success probability.

3. Flexible Incubation and Transatlantic Innovation

Joint Incubation of Unnamed AI Startups

The alliance provides a framework for rapidly co-incubating external projects, offering the agility to pursue emerging, high-growth opportunities across both established and novel AI verticals, as warranted by market conditions and technological advances.

A Nice Summary of What is likely to happen with this company. Source: Updated Perplexity AI App

Lots of buys this morning. I'm really pleased to hold here. This will take off sooner or later, imho. I have my computer turned off most of the time.

Very relaxed about this company and what is in store.

Over 2 million share buy at 4.15 @0.53p.

13 million buys posted after hours. That tells us a lot.